Table 2 Percentage differences in primary and main secondary efficacy endpoints between QD group and ADS group at 16-week
Outcome (%) | QD (n = 32) | ADS (n = 30) | Difference (95% CI) | P value† |
|---|---|---|---|---|
Mucosal healing | 25(78.13) | 18(60.00) | 18.13 (-6.9, 40.77) | 0.122 |
Endoscopic response | 29(90.63) | 24(80.00) | 10.63 (-9.78, 30.97) | 0.235 |
Clinical remission | 25(78.13) | 17(56.67) | 21.46 (-3.96, 43.90) | 0.071 |